Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase NA 3Phase 3 2Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 6Recruiting 5Terminated 2Not yet recruiting 2Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Breast Neoplasms 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Platinum × Clear all
NCT06351332 2026-05-22

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Dana-Farber Cancer Institute

Phase 1/2 Terminated
7 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01732640 2018-07-26

A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Terminated
9 enrolled 13 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡